Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review

Table 1

Phase 2 trials of erlotinib in colorectal cancer.

Study	Status	Results	NCT identifier
Erlotinib, capecitabine, and oxaliplatin	Completed	The arm with erlotinib showed higher response rate and PFS	NCT 00123851
Erlotinib alternating with chemotherapy for second-line treatment	Unknown	Pending	NCT00642746
Bevacizumab and erlotinib in combination with FOLFOX	Completed	High number of withdrawal due to toxicities limiting conclusion on efficacy	NCT00116506
Capecitabine in combination with erlotinib	Terminated	14 patients enrolled, severe toxicities median survival 76 weeks	NCT00459901
Dual epidermal growth factor inhibition with erlotinib and panitumumab with and without chemotherapy	Recruiting	Pending	NCT00940316
Erlotinib in treating patients with recurrent CRC	Completed	Pending	NCT00032110
Dual inhibition of EGFR signaling using cetuximab and erlotinib	Active, not recruiting	Pending	NCT00784667
Intermittent versus continuous Tarceva study	Completed	Pending	NCT01243047
Erlotinib and combination chemotherapy in treating mCRC	Completed	Pending	NCT0049101
Bevacizumab in combination with Xelox and Tarceva	Active, not recruiting	Pending	NCT01135498
Erlotinib in treating patients with history of stage 1, 2, or 3 colorectal cancer or adenoma	Recruiting	Pending	NCT00754494